We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Finsbury Wwide. | LSE:FWP | London | Ordinary Share | GB0003385308 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 632.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMWWH
Worldwide Healthcare Trust PLC
23 November 2016
London, UK, 23 November 2016
Edison issues update on Worldwide Healthcare Trust (WWH)
Worldwide Healthcare Trust (WWH) aims to generate long-term capital growth from investing in a portfolio of global healthcare stocks; a differentiating feature is the trust's c 15% exposure to emerging markets. Following a change in mandate in 2010, WWH now invests in all sectors of the healthcare industry. Performance versus its benchmarks is particularly strong over three, five and 10 years. Sam Isaly has been lead manager since launch in 1995; he is co-founder of the world's largest specialist healthcare investment company, OrbiMed Capital.
Following the recent US election with a win for Trump rather than Clinton, who was very vocal on drug pricing, WWH's share price has rallied (more strongly than the US healthcare sector). The current discount to cum-income NAV of 1.9% compares to a range of a 0.7% premium to a 13.0% discount over the last 12 months (average of 6.2%). It is also narrower than the average discounts of the last three, five and 10 years (range of 4.8% to 6.5%). Given WWH's focus on capital growth rather than income, it has a modest dividend yield, currently 0.8%.
Click here to view the full report
All reports published by Edison are available to download free of charge from its website: www.edisoninvestmentresearch.com
About Edison: Edison is an international equity research firm with a team of over 70 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-investment-research --------- ---------------------------------------------------- Twitter www.twitter.com/Edison_Inv_Res --------- ---------------------------------------------------- YouTube www.youtube.com/edisonitv --------- ---------------------------------------------------- Google+ https://plus.google.com/105425025202328783163/posts --------- ----------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABJBTTMBMTBBF
(END) Dow Jones Newswires
November 23, 2016 07:05 ET (12:05 GMT)
1 Year Finsbury Worldwide Pharm Chart |
1 Month Finsbury Worldwide Pharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions